Diabetes Clinical Trial Analysis Report 2023: Featuring 200+ Key Companies by DelveInsight

 Breaking News
  • No posts were found

Diabetes Clinical Trial Analysis Report 2023: Featuring 200+ Key Companies by DelveInsight

January 05
14:45 2023
Diabetes Clinical Trial Analysis Report 2023: Featuring 200+ Key Companies by DelveInsight
Diabetes Pipeline

DelveInsight’s ‘Diabetes Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetes pipeline domain.

For Diabetes emerging drugs, the Diabetes pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Diabetes pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Key takeaways from the Diabetes Pipeline Report

  • Over 200+ Diabetes pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetes market would significantly increase market revenue.
  • The leading Diabetes Companies developing novel drug candidates to improve the diabetes treatment landscape include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Promising Diabetes Pipeline therapies in various stages of development include LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.
  • The Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence R&D Diabetes. The Diabetes pipeline therapies under development are focused on novel approaches to treat/improve Diabetes.

 

Request a sample and discover the recent breakthroughs happening in the Diabetes pipeline landscape @ Diabetes Pipeline Outlook Report

 

Diabetes Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.

 

Find out more about the diagnosis and treatment of patients with Diabetes @ Diabetes Treatment Landscape

 

Diabetes Emerging Drugs Profile

  • Enavogliflozin – Daewoong

Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

  • Golimumab – Janssen Biotech

Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

 

Diabetes Pipeline Therapies and Key Companies

  • Daewoong Tradipitant: LY2963016
  • Janssen Biotech: Lantus
  •  Zealand Pharma: OAMs
  • Provention Bio: insulin glargine
  • BioRestorative Therapies: exenatide
  • Elevian: preexisting metformin
  • Kamada: insulin glargine
  • Adocia: sitagliptin
  • Oramed Pharmaceuticals: preexisting metformin
  • ImCyse: insulin glargine
  • Histogen: preexisting metformin
  • Novo Nordisk: ORMD-0801
  • Enthera: Cotadutide

 

Learn more about the Diabetes Emerging pipeline therapies @ Diabetes Ongoing Clinical Trials Analysis

 

Diabetes Pipeline Therapeutic Assessment

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Route of Administration

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • ·Molecule Type

Molecule Types

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Scope of the Diabetes Pipeline Report

  • Coverage- Global
  • Diabetes Companies- Daewoong Tradipitant, Janssen Biotech (JNJ: NYSE), Zealand Pharma (NYSE: ZLDPF), Provention Bio (NYSE: PRVB), BioRestorative Therapies (NYSE: BRTX), Elevian, Kamada (NYSE: KMDA), Adocia (NYSE: ADOC), Oramed Pharmaceuticals (NYSE: ORMP), ImCyse, Histogen (NYSE: HSTO), Novo Nordisk (NYSE: NVO), Enthera Bio (NYSE: ENTX), ActoBio Therapeutics, Japan Tobacco (NYSE: JAPAF), Avotres, and others.
  • Diabetes Pipeline Therapies- LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.

 

Dive deep into rich insights for Diabetes Emerging Therapies and assessment; visit @ Diabetes Emerging Therapies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetes: Overview
  4. Diabetes Pipeline Therapeutics
  5. Diabetes Therapeutic Assessment
  6. Diabetes – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Diabetes Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Enavogliflozin: Daewoong
  11. Mid Stage Products (Phase II)
  12. Golimumab: Janssen Biotech
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase II/I)
  15. IMCY-0098: ImCyse
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. ENT-001: Enthera
  19. Inactive Products
  20. Diabetes Key Companies
  21. Diabetes Key Products
  22. Diabetes Unmet Needs
  23. Diabetes Market Drivers
  24. Diabetes Market Barriers
  25. Diabetes Future Perspectives and Conclusion
  26. Diabetes Analyst Views
  27. Diabetes Key Companies
  28. Appendix

 

Trending Report:

 Tay-sachs Disease Or Gm2 Gangliosidosis Market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Categories